

Product Information Sheet

Product Name: Recombinant Mouse MOG Protein

Catalog Number: 55150-100, 55150-500, 55150-1000

Lot Number: See label on the vial

Amount/size: 100 μg, 500 μg, 1000 μg

Source: The sequence (Accession # NP_034944) corresponding to the extracellular domain of mouse MOG

along with a 6x His tag was expressed in *E. coli*. The recombinant mouse MOG (M-rMOG) was purified from urea denatured bacterial lysate using immobilized metal affinity chromatography

(IMAC). The molecular weight of the recombinant mouse MOG is 14.2 kDa.

Activity: Female C57BL/6NHsd and SJL/JCrHsd mice (9-10 weeks old) were immunized (s.c.) with 100

µg/animal of mouse rMOG in complete Freund's adjuvant followed by 400 ng/mouse injection of pertussis toxin on day 0 and day 2 (i.p.). Mice showed EAE symptoms such as limp tail, hind limb weakness, or hind limb paralysis after induction. Please note that no other EAE induction protocols

were tested including IFA/cytokine model.

Purity: Greater than 95% as determined by SDS-PAGE.

Endotoxin (EU/μg): Less than 0.1 EU per 1 μg of the protein as determined by Limulus Amebocyte Lysate (LAL)

quantitative kinetic assay.

Storage: The purified mouse rMOG is supplied as sterile and frozen at 1 mg/ml in 25 mM sodium acetate


buffer (pH=4.0). Store at 2-4 °C for immediate use within 3 weeks or at -80 °C for up to 12 months.

Avoid repeated freeze-thaw cycles.

Instructions:

Myelin Oligodendrocyte Glycoprotein (MOG) is a member of the immunoglobulin superfamily and is expressed exclusively in central nervous system (CNS). Although MOG protein constitutes only 0.01-0.05% of the CNS myelin proteins, it was demonstrated that MOG protein is a crucial autoantigen for multiple sclerosis in humans and experimental autoimmune encephalomyelitis (EAE) in rodents and monkeys (1-5).

The purified mouse rMOG is recommended for in vitro studies such as T cell and B cell responses, cytokine response, antigen presentation, Western blotting, and ELISA as well as for in vivo study such as EAE induction in mice. The following dosages are recommended: 5-20 µg/ml for in vitro study and 50 µg per animal for in vivo study (1-5). Please note, mouse MOG must be thoroughly mixed directly with Complete Freund's Adjuvant (CFA). Do not dilute recombinant mouse MOG with buffers that have pH greater than 4.5! Protein will precipitate at pH higher than 4.5!






Figure 1. Mouse rMOG on SDS-PAGE.

Purified M-rMOG was loaded onto 10-20% Tris-HCl gel at 3 μg/well and resolved at 200V for 60 minutes. Protein markers and purified M-rMOG (14.23 kDa) are indicated. CL=Crude Cell Lysate, FT=Flow Through, and P=Purified M-rMOG.

Figure 2. An Example of EAE Data Using Mouse rMOG. Five female C57/BL6 mice (9 weeks old) were injected with 100 µg/animal mouse rMOG (Cat. 55150) in CFA (total injection volume is 100 µl/site) at two flank sites subcutaneously (s.c.) along with 400 ng/animal of Pertussis Toxin (PT) on day 0 and 2. EAE scores may vary due to the animal health and housing conditions. This graph is for the reference only.

©AnaSpec, Inc. 34801 Campus Drive, Fremont, CA 94555 Tel: (800)-452-5530 | service@anaspec.com | www.anaspec.com

Related Products

Product Name	Cat. #
Recombinant human MOG (1-125)	55158
Recombinant rat MOG (1-125)	55152
SensoLyte® Anti-Human MOG (1-125) Mouse IgG Specific ELISA Kit	55153-M
SensoLyte® Anti-Human MOG (1-125) Rat IgG Specific ELISA Kit	55153-R
SensoLyte® Anti-Human MOG (1-125) Human IgG Specific ELISA Kit	55153-H
SensoLyte® Anti-Mouse MOG (1-125) IgG Quantitative ELISA Kit	55156
SensoLyte® Anti-Rat MOG (1-125) IgG Quantitative ELISA Kit	55157

References:

- 1. Jayaram Bettadapura et.al. (1998) Journal of Neurochemistry 70 (4): 1593-1599
- 2. Alfred R Oliver et al (2003) Journal of Immunology 171:462-468
- 3. Hans-Christian Von Budingen et.al. (2001) Journal of Clinical Immunology 21 (3): 155-170
- 4. Jerri-Anne Lyons et.al. (1999) European Journal of Immunology 29: 3432-3439
- 5. Hans-Christian Von Budingen et.al. (2004) European Journal of Immunology 34: 2072-2083

For Research Use Only!